Tuesday, October 2, 2007

Breast milk boosts brain development in preemies


CTV.ca News Staff

Even extremely low birth weight premature babies should be given breast milk while they are in a hospital's intensive care unit because it appears to boost their mental development, concludes a study in the journal Pediatrics.

The study found that preemies fed breast milk had greater mental development scores at 30 months of age than infants who were not fed breast milk.

Moreover, infants fed breast milk were less likely to have been re-hospitalized after their initial discharge than were the infants not fed breast milk.

The study involved 773 U.S. babies born extremely underweight -- less than 2.2 pounds (1 kg) -- between 1999 and 2002. The children were divided into five groups by the quantity of breast milk they ingested while in the NICU.

The majority of the infants had been given at least some breast milk while in the NICU administered by a feeding tube that dripped the breast milk into their stomachs; 593 ingested some breast milk, while 180 ingested none.

Both groups experience the same amount of physical growth. But the babies given breast milk got higher scores on a test measuring their overall intelligence at 30 months of age, with the highest scores showing up among the children who had received the most breast milk as infants.

As well, for every 10 mL/kg per day increase in breast milk, the risk of rehospitalization between discharge and 30 months decreased by five per cent.

Mothers who provided breast milk for their infants tended to have more education than those who did not. However, in their analysis of the data, the researchers mathematically compensated for the mothers' educational levels.

With this adjustment, the researchers concluded that consumption of breast milk had a positive effect on infants' mental development scales, independent of mothers' educational levels.

"These findings strongly suggest that, whenever possible, preterm infants should routinely be given breast milk during their stay in the intensive care unit," said Dr. Duane Alexander, director of the National Institute of Child Health and Human Development, which backed the study.

Previous studies have found that infants who ingest breast milk are able to leave the neonatal intensive care unit sooner than infants receiving formula.

The Canadian Paediatric Society recommends that children be breastfed exclusively for at least six months.

Monday, October 1, 2007

North Carolina’s Northeast Ripe for Biotech Industries


Regional Development Commission forms alliance to help farmers and pursue additional biotech companies

North Carolina’s Northeast Ripe for Biotech Industries
Edenton, NC, September 27, 2007 --(PR.com)-- North Carolina’s Northeast Commission is forming alliances with those in the biotechnology industry in an effort to help farmers diversify uses for their land and further attract biotechnology companies to the region. In a meeting last week, the Northeast Commission led a forum with biotechnology consultants and regional stakeholders to validate a new industry niche in the biotechnology arena for North Carolina’s Northeast Economic Development Region. “Our job at the Northeast Commission is to increase the region’s capacity for new jobs and to diversify our economy. We have a tremendous number of assets and resources in our region that, when combined, offer us a world class niche in our economy,” says Vann Rogerson, Commission President & CEO. “We even want to find ways for farmers to diversify uses for their land and identify our niche in supporting biotechnology development in the region.”

The group is also working to develop a plan for new technologies to be researched and to determine how to better link these resources together to collectively offer an enticing business venture to prospective bio companies. Dr. Ron Heiniger oversees North Carolina State University’s agricultural research and support operating at the Vernon James Research Center in Roper and is a strong proponent of the regional initiative. In 2005, the Northeast Commission, NCSU and North Carolina Department of Agriculture, along with many of the attending stakeholders, successfully recruited Ventria, a California biotech company, to grow rice in the northeastern region of North Carolina. “This company asked our area to grow bio-engineered rice that produces proteins valuable to the nutraceuticals industry. From this experience, we have seen a real opportunity for a new niche in plant-made biotech products for the northeast region,” says Heiniger. The NCSU staff at the Vernon James Center grow plants for applied research to help farmers stay current in the latest technologies.

A regional grant from the North Carolina Biotechnology Center along with funds from the Northeast Commission has enabled the region to look at the development of the biotech industry in the Northeast Region from a scientific and economic perspective. RTI, a Raleigh based world renowned independent research organization with a distinguished history in scientific research and technology development, is studying the region and will make recommendations for biotech development specific to North Carolina’s Northeast. RTI will assess the assets of the region and match the strengths of North Carolina’s Northeast to projects in the industry. The recent meeting is an important step in this process.

“We expect that the RTI study will confirm the viability of biotech development in the region. The farming community is excited about this opportunity that the Northeast Commission initiative offers,” said Joe Landino, a member of the Blackland Farm Managers Association.

Represented at the meeting were the North Carolina Biotechnology Center, The Bio Network, North Carolina Department of Commerce, NEED (Northeast Economic Developers), community colleges, NCSU, and Elizabeth City State University along with AVOCA, a world-recognized leader in plant extractions.

“We certainly see opportunities in areas like plant-made products and biofuels, and we expect our consultant to verify this and other opportunities in Northeastern North Carolina. This initiative will certainly help our local economy,” said Ernest Burden, Northeast Commission board member from Washington County.

North Carolina’s Northeast Commission is dedicated to increasing the standard of living for citizens in its sixteen-county region through tourism, industrial, and business development. The 16 counties that comprise the regional Commission are: Beaufort, Bertie, Camden, Chowan, Currituck, Dare, Gates, Halifax, Hertford, Hyde, Martin, Northampton, Pasquotank, Perquimans, Tyrrell, and Washington. For more information about the North Carolina’s Northeast Commission, contact us at www.ncnortheast.com and www.visitncne.com.

Saturday, September 29, 2007

Bird flu virus can pass from mother to fetus: study


An autopsy performed on a pregnant Chinese woman who died from H5N1 avian flu infection showed the virus passed to the fetus, Chinese researchers report in the journal The Lancet.

The researchers, from several institutes and universities in Beijing, found the "transplacental transmission" of the H5N1 virus interesting, since the virus doesn't normally affect the fetus with common flu infections.

The researchers found the fetus' lungs contained many infected cells, but didn't create the severe damage seen in the lungs of the 24-year-old pregnant woman.

The scientists suggest the lack of damage was likely due to the fact that the immune system of the fetus was not developed and therefore its body didn't mount an attack on the virus and didn't release chemicals -- cytokines and chemokines -- that may worsen lung damage.

The report is the first to contain autopsy data for either a pregnant woman or a fetus.

It's also the first to come out of the Infectious Disease Center at Peking University in Beijing, which was created after the epidemic of SARS and that is now intensely studying the H5N1 strain of avian flu.

"The work helps us to understand H5N1's high fatality rate, as well as serving as model for global collaboration in the field of emerging infectious diseases," said Dr. Ian Lipkin of Columbia University in New York, who directed the study.

The researchers also performed an autopsy on a 35-year-old man and found genetic material from the virus in the man's lungs, as expected. But they also found the material in the man's brain, intestines, and in immune system cells in the blood and the liver.

The damage in the lungs was particularly severe, lending weight to the theory of a "cytokine storm" -- the idea that the immune system goes into overdrive against the virus in some cases, and sends out a swarm of chemicals that end up killing the patient.

The H5N1 strain of bird flu has killed 60 per cent of the humans it has infected. To date, all pregnant women known to have been infected -- about a half-dozen -- have either died or had a spontaneous abortion.

Although at least 200 people have died from H5N1, there has been a pitiful lack of autopsy data available for scientists to study. Most of the deaths have occurred in countries where autopsies are not performed for cultural reasons.

FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age First and Only Nasal Spray Influenza Vaccine for Young Childre


MedImmune, Inc. (www.medimmune.com) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of FluMist(R) (www.FluMist.com) (Influenza Virus Vaccine Live, Intranasal) in children two to five years of age. FluMist is now approved for active immunization for the prevention of disease caused by influenza A and B viruses in individuals two to 49 years of age. Only one manufacturer had previously been licensed in the United States to produce influenza vaccine, in the form of a flu shot, for children under four years of age.

Gaihersburg, Md. (PRWEB) September 22, 2007 -- MedImmune, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of FluMist(R) (Influenza Virus Vaccine Live, Intranasal) in children two to five years of age. FluMist is now approved for active immunization for the prevention of disease caused by influenza A and B viruses in individuals two to 49 years of age. Only one manufacturer had previously been licensed in the United States to produce influenza vaccine, in the form of a flu shot, for children under four years of age.

News Image
MedImmune anticipates shipping FluMist with the expanded label to health care providers in the coming days so that vaccinations may be offered to eligible individuals ahead of and throughout the upcoming influenza season.

With the new, refrigerated formulation approved in January, the results from our head-to- head study published in the February issue of The New England Journal of Medicine, and the expanded age indication now within the label, it is an exciting time for FluMist.
"As a company dedicated to innovative advancements in pediatric medicine, MedImmune is delighted to be able to offer FluMist as an option for children as young as two years old to help protect them from influenza," said James F. Young, Ph.D., president, research and development. "With the new, refrigerated formulation approved in January, the results from our head-to- head study published in the February issue of The New England Journal of Medicine, and the expanded age indication now within the label, it is an exciting time for FluMist."

In a pivotal study that included more than 4,000 children between the ages of two and five years of age during the 2004-2005 influenza season, there was a 54 percent reduction in cases of flu and flu symptoms in children who received FluMist compared with those who received the traditional flu shot (4.5 percent vs. 9.8 percent, respectively).(1) In the study, FluMist demonstrated a reduction in influenza rates compared to the inactivated vaccine against strains that were both matched and mismatched to the vaccine.

In 48 completed clinical trials, more than 48,000 subjects ranging in age from six weeks to more than 90 years of age received FluMist. In addition to the clinical trial experience, approximately 60,000 doses of FluMist have been administered in two post-marketing studies, and approximately seven million doses of FluMist have been distributed for use in individuals five to 49 years of age following licensure of the product in 2003 through the 2006-2007 influenza season. FluMist is different from the flu shot in that it uses live, attenuated - or weakened - viruses within the vaccine to help stimulate an immune response that is designed to closely resemble the body's natural response to an influenza infection.

"The FDA approval of FluMist for young children is important because these young kids have very high attack rates for influenza, often require medical evaluation for their influenza illness, and can spread influenza easily to others," said Pedro Piedra, M.D., professor, Department of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine. "Also, the live attenuated influenza vaccine is quite effective in helping prevent influenza and is generally very acceptable to children and their parents since it is administered by nasal spray rather than a shot."

Influenza's Impact on Young Children
The flu is most prevalent in school-age children, as the virus travels easily from person to person and because children in this age group spend a large part of their day in close contact with other children. Children two to 17 years of age are twice as likely to get influenza than adults, including the elderly.(2) During a widespread outbreak, the rate of flu infections can exceed 30 percent in school-age children. Each year, up to 60 million Americans get the flu, according the U.S. Centers for Disease Control and Prevention (CDC). Resulting complications cause more than 200,000 hospitalizations and approximately 36,000 deaths in the U.S. annually.
Protection Against Matched and Mismatched Strains of Flu

FluMist has demonstrated in clinical trials that it helps provide protection against flu strains both matched and mismatched to those used in the vaccine. Mismatched strains are circulating strains that are different from those included in manufacturing the season's flu vaccines. According to CDC data, vaccine mismatch has occurred to varying degrees in five of the last 11 flu seasons, most recently during the 2005-2006 season.

About FluMist
FluMist is a live attenuated influenza virus vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life- threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

Do not administer FluMist to children less than two years of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children less than five years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.

If Guillain-Barre syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.

Most common adverse reactions (occurring in 10 percent or more of individuals receiving FluMist and at a rate at least five percent higher than in those receiving placebo) are runny nose or nasal congestion in recipients of all ages, fever more than 100 degrees Fahrenheit in children two to six years of age, and sore throat in adults.

FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.

Please see complete Prescribing Information for FluMist, call 1-877-FLUMIST (1-877-358-6478) or visit www.flumist.com for additional information.

About MedImmune
MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc . For more information, visit MedImmune's website at http://www.medimmune.com
(1) Data is representative of indicated population. Results for full study population are included in Prescribing Information.
(2) Glezen, W et al, Influenza virus infections in infants, 1997. Pediatric Infectious Disease Journal. 1997;16(11):1065-1068.

###

Sunday, September 16, 2007

Cholesterol Levels - The Good, The Bad, and Management Of

By: Jack Koetting

What is cholesterol, and is it all bad? What's the difference between LDL and HDL cholesterol? What are the healthy or normal cholesterol levels you should strive for?

In this article, I'll explain what happens when your cholesterol levels aren't normal, as well as some of the ways to manage them, so that you can be better educated and proactive where your health is concerned, and maybe even extend your life.

First of all, cholesterol is a waxy substance found in cells in all parts of the body. And no, it is not all bad. In fact, cholesterol is necessary for building and regenerating cells. It also insulates nerves and produces hormones in the body. The key is maintaining normal levels.

Where does cholesterol come from? About 75% of the cholesterol in our bodies is manufactured in the liver, and the other 25% comes from food, mostly meat and dairy products. If your liver produces too much cholesterol, that is when the levels become abnormal or unhealthy, and a method for bringing them back in balance becomes a necessity in order to preserve cardiovascular health.

This is especially important in people with diabetes, or metabolic syndrome (sometimes referred to as pre-diabetes.) Unhealthy cholesterol levels, when combined with weight gain and increased blood pressure, can lead to all kinds of health challenges.

IT IS IMPORTANT TO KNOW YOUR NUMBERS

Notice the plural, because it is not only total cholesterol or just the bad cholesterol number that is important. Complete cholesterol care implies being aware of all the numbers.

So what are the numbers you should know that make up the complete cholesterol picture?

First is the LDL or bad cholesterol. This is the component that when it becomes elevated, causes buildup on the walls of the arteries. As this buildup hardens, it becomes plaque, which increases your risk of cardiovascular disease (CVD). Science is proving that this buildup starts to develop in late teens and early twenties, and continues progressively as we age.

Of course as this buildup continues, it starts to narrow the opening in the arteries, restricting blood flow and raising blood pressure. Left unchecked, it can continue until it ruptures which causes a clot to form, totally cutting off the flow of blood.

If this clot is in the area leading to the heart, it is a heart attack. If it is in the arteries leading to the brain, that is a stroke. Both are considered cardiovascular disease.

LDL levels of greater than 190 are considered dangerous. 160 to 189 is considered poor, 130 to 159 is fair, and readings less than 129 are considered healthy. Some doctors are suggesting levels be below 100, and recent research is showing that if we can reduce our LDL to less than 70, we can actually start to reverse the plaque buildup.

The next number to be aware of is HDL, or the good cholesterol, which reduces your risk of CVD. In fact, your HDL number is becoming much more important because research has shown that for every 1% you reduce your LDL or bad cholesterol, you get about a 2% reduction in cardiovascular risk. But for every 1% you increase your HDL, you get a 3% reduction in risk. What should your HDL be? Healthy levels for men are above 40, and for women, it should be above 50.

Total Cholesterol or TC is the addition of your LDL, HDL and a component known as VLDL. Healthy levels are anything under 200. Another important number to be aware of is your cardiovascular risk ratio. This number is determined by dividing Total Cholesterol by HDL. This number should be below 5, with the optimal amount of 3.5 or lower.

Where do triglycerides come from? Fats consumed in our diet, or made in the body from carbohydrates, cause triglycerides in the blood. Some calories are converted to triglycerides and move into the fat cells for storage. So how do those numbers stack up?

Triglyceride levels of less than 150 are considered acceptable. Levels from 150 to 199 indicate moderate risk, 200 to 499 indicate high risk, and levels in excess of 500 indicate extreme high risk.

If it's confusing to remember what's good and what's not, an easy way to remember the different parts of the total picture is "L" stands for "lethal" LDL, "H" stands for "healthy" HDL, and "T" stands for "treacherous" triglycerides.

METHODS FOR DEALING WITH UNHEALTHY CHOLESTEROL

There are different methods a person can use for improving one's cholesterol levels. The most widely known is through the use of special cholesterol lowering prescription drugs called "statins". Statins such as Lipitor, Zocor, Crestor, and others represent nationally a 25 Billion Dollar per year treatment option. They have proved themselves effective at lowering the LDL segment of the cholesterol picture, however they do very little to reduce triglycerides or raise the HDL.

Besides, statins sometime carry very significant side effects, and therefore some people can't take them. What are some of these documented side effects?

The Statin Effects Study concluded that the top two are possible liver and muscle damage. However, there are also lesser known effects such as sudden memory loss, increase in eye cataract risk, suppresses the body's natural immune function, increased cancer risk, kidney and nerve damage, depletes CoQ10 levels (necessary for healthy heart function), sleep disturbance, blood sugar or blood pressure changes, and sexual dysfunction.

According to the drug manufacturers, only an insignificant number of patients are affected by these side effects. But if you're one of them, is it "insignificant" for you? What you will hear more and more from the drug companies, is that they also will admit that just lowering the LDL is not enough.

Combination therapy will become the new buzz word. It means adding additional drugs to raise the good cholesterol, or lower triglycerides or blood sugar. Of course, it's highly likely that these additional drug additives will have their own set of additional side effects.

In fact, reports on the recent results of a clinical study by one of the leading pharmaceutical company's combinations to try to raise the HDL led to "pulling the plug" on the whole experiment. Why, you ask? According to the report, an "unacceptable number of people died" while taking the combination therapy. Makes me wonder what number of people would be "acceptable".

Do we see increased costs and co-pays in our futures? I believe you can bank on it. Some people feel, and I'm one of them, that even the cheapest co-pay is more than they're willing to risk their quality of life for.

So are there other, safer alternatives for you? The answer is yes. In fact, according to the National Cholesterol Education Program (NCEP) guidelines for healthcare providers, statin drugs should not be the first treatment option offered. According to these guidelines, Therapeutic Lifestyle Changes (TLC) should be used as a first approach.

What are some of the features of TLC? Increase of soluble fiber, regular exercise, and weight reduction are the main ones. When it comes to diet, watch your fat intake, and eat more fruits and vegetables.

In addition to soluble fiber, other methods that can control cholesterol levels are the use of plant sterols or stanols, and a natural component called policosanol, from sugar cane, which blocks the enzyme in the liver that produces cholesterol. Statins block the same enzyme; however, the difference is that the policosanol does not damage the liver. Also ancient Chinese medicine has used a particular extract from the chrysanthemum plant to help in the breakdown of cholesterol.

If you're concerned about safety and effectiveness, choose a natural solution with solid clinical evidence, that incorporates multiple methods, and raises HDL in addition to lowering LDL.

Be proactive in your own health, be educated on your cholesterol situation, make the right lifestyle choices, and you'll improve your chances of living longer.

Additional information on lowering cholesterol can be found in "Your Guide to Lowering Cholesterol with TLC" by the US Nat'l Institutes of Health. NIH Publication 06-5235

Article Source: http://nichearticlesdirectory.com

Causes Of Insomnia

By: Brad Martinson

According to the U.S. Department of Health and Human Services, approximately 60 million people suffer from insomnia.

Sleep is an essential part of good health. A good night's sleep can help you feel good, look healthy, work effectively and think clearly.

But sleep is not always so easy to come by. If you sometimes have trouble falling asleep or staying asleep, you're not alone. A 1991 Gallup study found that more than one third of all Americans suffer occasional or chronic insomnia.

Insomnia is the sensation of daytime fatigue and impaired performance caused by insufficient sleep. In general, people with insomnia experience an inability to sleep despite being tired, a light, fitful sleep that leaves them fatigued upon awakening, or waking up too early. Under debate is the question of whether insomnia is always a symptom of some other physical or psychological condition or whether in some cases it is a primary disorder of its own.

People often are surprised to learn that daytime drowsiness is not an inevitable, harmless byproduct of modern life, but rather a key sign of a sleep problem that could be disastrous if not treated.

Recent figures show that nearly a quarter of the population regularly cannot go to, or remain asleep, and every year doctors write out more than 14 million prescriptions for sleeping tablets.

The worst part of insomnia is wanting to sleep but being unable to. The mind races and is unable to rest and that makes you overly tired and barely able to function the next day. Sometimes insomnia lasts longer than just a few nights.

Chronic insomnia may also be primary or secondary, depending on the cause: Primary chronic insomnia occurs when it is the sole complaint of a patient.Secondary chronic insomnia is caused by medical or psychiatric conditions, drugs, or emotional or psychiatric disorders.

There are several known causes for. It can be due to a medical condition, such as chronic pain from rheumatism or arthritis. It may be chemical, as a result of drinking tea, coffee or alcohol. Chronic or long-term insomnia is often associated with depression or anxiety, and environmental factors certainly contribute.

And sleepless nights, staring wild-eyed into the darkness, are worse than bad dreams,

For too many people - an estimated 9 percent of the American population - a good night's sleep is an elusive goal. The consequences of fatigue from chronic sleeplessness include accidents in the car and at work, a dramatically increased risk of major depression, and worsening physical illness.

Immediate relief is available, in the form of hypnotic agents, for persons who have difficulty in falling or remaining asleep or who cannot obtain restful, restorative slumber. However, long-term improvement usually involves behavioral therapy. These therapeutic approaches must be integrated if the patient's short- and long-term needs are to be addressed.

Article Source: http://nichearticlesdirectory.com

Saturday, September 15, 2007

Essence of g: scientists search for the biology of smarts

Nearly a century ago, British psychologist Charles Spearman started what remains one of the most passionate debates about people's mental abilities. Spearman declared in 1904 that he had found the way to measure an individual's core intelligence. Using a mathematical method called factor analysis, Spearman noted that individuals score similarly on many items from a range of mental tests, some resembling today's IQ tests. Scores on these correlated items yielded a single factor, which Spearman called the general or g factor, that he deemed to be a marker of a person's facility for reasoning about any and all mental tasks.

Although Spearman had difficulty defining precisely what g measured or how it worked, he regarded it as more than a cold statistic. In his opinion, g tapped into "mental energy" that sprang from an unknown physical source. A meager trickle of this intellectual force mires people in retardation, a steady stream of it produces average intelligence, and a gusher promotes genius.

Scientists are still devoting considerable mental energy to exploring Spearman's notion. Enthusiasts for g hope to identify the measure's genetic and neural roots. Preliminary findings offer both encouragement and disappointing reminders of how little is known.

At the same time, critics regard g as a meaningless statistic that doesn't generate testable predictions about how intelligence works. Considerable leeway for personal judgment exists in conducting the type of mathematical calculations that Spearman did to come up with g, they argue. As a result, mental-test scores yield a single g in some studies but not in others.

Critics also charge that mental-test scores mainly reflect a person's social and emotional preparation for solving test problems, which are saturated with cultural assumptions.

Proponents of g couldn't disagree more. In his book The g Factor (1998, Praeger), Arthur R. Jensen of the University of California, Berkeley, presented accumulating statistical evidence for g that he says makes it imperative to discover what brain processes cause individual g differences. Other proponents say that their argument is being bolstered by research that's closing in on intelligence genes.

GENE HUNT Robert Plomin of the Institute of Psychiatry in London stands at the forefront of such research. "g shows significant genetic influence," he says. Plomin points to dozens of twin and adoption studies indicating that genes contribute substantially to individual differences in g.

Such studies find that genetic influences on g are modest among infants and children but become progressively stronger throughout adulthood. This suggests that, as people grow older, they find and create environments congenial to promoting their own genetic strengths, Plomin theorizes. "It may be more appropriate to think about g as an appetite rather than an aptitude," he says.

Many genes undoubtedly contributing in a minor way to differences between individuals on g or IQ scores, Plomin says. Such genes have so far eluded DNA researchers, however.

Consider the highly publicized link of a gene variant on chromosome 6 to high IQ (SN: 5/9/98, p. 292). In tests on 51 children, one form of a gene occurred more frequently in children with high IQ scores than it did in those with average IQs. However, this genetic disparity disappeared in a sample of more than 200 children, the same scientists reported in the November 2002 Psychological Science. Future research will need to compare tens of thousands of DNA markers across the genome in thousands of high- and average-g volunteers, says Plomin, a coauthor of the study.

A possible genetic clue to intellect and how it ages comes from a Scottish study led by Ian J. Deary of the University of Edinburgh. His team obtained IQ scores at age 11 and again at age 80 for 466 men and women of average intelligence. The 121 individuals possessing at least one copy of a specific variant of the apolipoprotein E gene, which influences brain-cell repair, performed as well as the rest at age 11. But at age 80, participants who had this gene form still scored in the average-intelligence range but at an average of 4 IQ points below their peers.

The same apolipoprotein E gene variant has been linked with a susceptibility to Alzheimer's disease, suggesting that lower IQ scores in the Scottish sample reflect the early stages of that brain disorder. However, the number of those with the critical variant who displayed an IQ drop greatly exceeded the expected number of Alzheimer's disease cases in this sample, Deary says. The apolipoprotein E gene variant may instigate intellectual losses in elderly people who still exhibit average intelligence and healthy brains, he proposes.

Whatever the specific genes underlying g, large-scale studies of twins now suggest that genes largely coordinate the capability of high-g individuals to make simple perceptual discriminations more quickly than average-g people do. Two such studies were recently completed in Australia, by Michelle Luciano of the University of Queensland in Brisbane and in the Netherlands, by Danielle Posthuma of Vrije University in Amsterdam. Genes also foster a tendency for the brain to grow somewhat larger, relative to body size, in high-g individuals, Posthuma says.

These findings fit with a current theory that high intelligence arises from the coating of brain cells with especially large amounts of the fatty substance called myelin. Thick myelin may speed signal transmission. Thicker myelin coats translate into brains that are larger and can better coordinate rapid perceptual decisions, Posthuma says. "Genes important for myelination also may be important for cognition," she notes.

Using IQ instead of g, Paul M. Thompson of the University of California, Los Angeles and his colleagues found a link between high scores and a greater density of neurons in the brain's frontal lobe. Their 2001 study of Finnish twins indicates that genes exert a substantial influence on the density of frontal lobe neurons.

Neuroscientist Douglas Wahlsten of the University of Alberta in Edmonton says that none of these genetic and physiology studies defines a g factor. From his perspective, there is no genetically ingrained brain feature that determines a person's capacity for thinking or learning. This renders the search for intelligence genes futile, Wahlsten asserts.

Instead, he says, a person's genes flexibly participate in the process of brain development. Complex networks of interacting genes, which function in various ways depending on environmental forces, contribute to learning and intelligent behavior. Scientists need to specify these networks and how they work in particular contexts, in Wahlsten's view.

VANISHING ACT For a measure that inspires so much biological interest, g has a bad habit of disappearing when mental tests broaden their scope, asserts John Horn of the University of Southern California, a longtime critic of g theory. Other researchers contend that it is just an artifact of statistics or cultural variation.

When Horn performs factor analysis on a battery of tests that cover a wide range of mental abilities, he finds not one factor but as many as 10. These include:

* fluid reasoning, which is the capability to solve problems using unfamiliar information or procedures;

* comprehension-knowledge, a compendium of prior verbal and procedural experience;

* long-term memory;

* short-term memory;

* quantitative knowledge.

Several of these factors correspond to some of the "multiple intelligences" proposed by Harvard psychologist Howard Gardner.

What proponents of general intelligence refer to as g corresponds to only one or two of these many factors, depending on the nature of the mental tests being investigated, Horn says. "There is no g," he contends. "The emperor is naked:

Support for Horn's argument comes from a study of mental growth directed by John J. McArdle of the University of Virginia in Charlottesville. McArdle's group analyzed scores on a broad battery of tests administered to nearly 1,200 people ranging in age from 2 to 95. Each participant again completed the age-adjusted tests between 1 and 10 years later. Statistical analyses indicated that scores of the various mental abilities rose and fell along separate trajectories over time, the researchers reported in the January 2002 Developmental Psychology. A single g factor can't account for the divergent ways these thinking faculties develop, McArdle says.

Of course not, argues Peter Schonemann of Purdue University in West Lafayette, Ind. His research indicates that g is simply a statistical byproduct of the way mental tests are constructed. In fact, any set of moderately correlated findings, such as the number of toys and books that individual children have, yields data that can be transformed into a general factor having nothing to do with any "general ability," Schonemann holds. The various sections of mental tests have been painstakingly designed to contain items that are comparable in difficulty. This deep well of positively correlated items serves up a general factor on demand, he says.

People's IQ differences stem largely from the extent to which individuals' social and emotional background prepares them for mental tests, proposes Ken Richardson of Open University in Durham, England. In a review of the scientific literature on g and IQ, he concludes that middle-class children draw on extensive experience in manipulating written words and numbers to recognize the nature of nonverbal intelligence problems. This occurs even on those tasks that test developers argue are uninfluenced by culture, Richardson says.

These items typically require a child to look at a set of abstract forms, discern a pattern in the set, and then choose an abstract form that fits into the overall pattern. In these cases, the successful test taker needs to know to read symbols from the top left to the bottom right of a page, for instance.

Other qualities grounded in a person's experience, such as having an academic orientation and believing in one's capability to carry out a course of action, also affect performance on such tests, Richardson theorizes. These influences would ensure that g correlates moderately with education levels and job performance. The spread of formal education and literacy can probably take much of the credit for the escalation of IQ scores--5 to 25 points each generation--in Western populations over the past several generations, the British psychologist argues.

PRACTICAL SMARTS Richardson's argument resonates among African villagers living on the shores of Kenya's Lake Victoria. The higher their school-age children scored on a test of practical knowledge about herbal medicines used in their families, the lower the same kids scored on academic intelligence and achievement tests, says Robert J. Sternberg of Yale University.

Sternberg and his coworkers studied 85 Kenyan children, ages 12 to 15. In many of their families, parents spend much time teaching children practical types of knowledge, such as which plants to use for common medical ailments. Children exposed to extensive practical knowledge at home generally did poorly at school and on standard intelligence tests, Sternberg's team reported in 2001. Children whose parents emphasized academics got the best grades in school and the highest IQ scores but lacked a grasp of practical knowledge.

These findings underscore the importance of Western-style schooling for developing skills required to succeed on intelligence tests, Sternberg holds. Children who opt to develop other skills generate forms of intelligence that have nothing to do with g scores.

Even if g doesn't explain all aspects of intelligence, there are innovative ways to explore whether it has neural foundations, remarks Michael Atherton of the University of Minnesota in Minneapolis. In two brain-imaging studies directed by Atherton, novice players of chess and the Japanese board game called go showed widespread, largely comparable brain activation as they pondered moves when presented with arrays of game pieces. However, the two games seem to draw on different strategic skills. Unlike chess, go doesn't contain individually identified pieces that move in unique ways.

Atherton's findings, which need to be confirmed in expert chess and go players, suggest that a single network of brain regions underlies g and fosters strategic thinking, he says.

Still, he remarks, the scientific game is far from over. As of now, g remains a statistical entity in search of a biological identity.
COPYRIGHT 2003 Science Service, Inc.
By Bruce Bower

Manuscripts as fossils: population-biology equations estimate medieval texts' likelihood of survival

Through the ages, innumerable texts have been consumed by fire, war, theft, and other disasters. Each ancient or medieval manuscript in existence today has its own story of survival against the odds, whether the document was tucked away in an obscure monastery for a millennium or stolen by Vikings and passed from collector to collector. Manuscript experts have long puzzled over the question, what fraction of ancient works has survived?

Paleontologist John Cisne of Cornell University brings a fresh approach to this problem. He regards handwritten medieval manuscripts as fossils from an extinct population. Using equations from population biology, he has created a mathematical model that suggests, happily, that we have at least fragments of the majority of popular medieval titles.

"It looks as if we've got a representative sample of the books in circulation 1,000 or 1,200 years ago, not just a few rare flukes," Cisne says.

Until the invention of the printing press in the 15th century, reproduction of manuscripts had a lot in common with replication of organisms, Cisne argues. Each new manuscript had to be transcribed from an existing "parent" copy, so the more copies in circulation, the more new ones that could be produced. Cisne hypothesized that the number of copies of a given text should grow according to population biology's logistic model: The population would at first increase exponentially, as cliche rabbits do, then gradually level out as it approached the maximum number of organisms that the environment could sustain. For manuscripts, that would be the number of libraries and individuals who wanted a copy.

To test this model, Cisne examined four scientific texts by the Venerable Bede, an 8th-century scholar who is one of the most thoroughly cataloged of medieval authors. By looking at how many copies of his works survive today and in which century, from the 8th to the 15th, each was produced, Cisne found that these texts do indeed fit the logistic model. He describes his work in the Feb. 25 Science.

NUMBERS GAME With his model, Cisne estimates that the likelihood that a popular medieval text would have gone extinct between its creation and the present day is less than 7 percent. This estimate fits well with the availability of the Bede's other works. Of his 35 known books, 32 have survived in some form.

"The numbers are in the right ballpark," Cisne says.

"It's very exciting work," says Florence Eliza Glaze, a historian of medieval medicine at Coastal Carolina University in Conway, S.C. "Classical scholars tend to work with anecdotal evidence, and most of us don't do statistical analyses. This is a great opportunity to get people talking across disciplines."

Glaze cautions that while the new model works well for the four scientific works that Cisne studied, it makes many assumptions that will probably work less well for other texts. One problem is that Cisne assumes that manuscripts have a constant death rate, whereas the destruction of manuscripts tends to be highly episodic. For instance, many manuscripts were burned during the dissolution of the English monasteries in the 16th century, for example, and others were destroyed during the French Revolution, when the revolutionaries used manuscript parchment for rifle cartridges.

Cisne agrees with this caveat. "I specifically looked at Bede's scientific works because they looked like idealized cases where the model might apply," he says. They were widely owned by the clergy, the educated elite, and the commercial classes and had no political or religious content that might lead them to be targeted for destruction.

When Cisne applied his model to Bede's Ecclesiastical History of the English People, which was held primarily by monasteries, the equations failed to capture the book's population dynamics. Cisne is now looking for ways to refine the model to deal with such situations.

"This is how science works--you find a first-order model that works in simple situations, then go on to look at complex situations and see if the model can be modified," Cisne says.

LOST IN TRANSLATION Other analogies between organisms and manuscripts may be worth exploring, Cisne says. The world of books has its own versions of invasive species and mutations, for instance. In 12th-century Spain, early medieval geometry textbooks quickly became obsolete after state-of-the-art Arabic volumes arrived on the scene. Furthermore, every time a scribe copied a manuscript, he inevitably introduced small errors. Scholars of ancient texts use many of the same techniques that evolutionary biologists do when investigating which manuscripts predate others and what the original version must have said.

To study evolution of both organisms and manuscripts, Cisne is now using tools from information theory, which considers transmission errors in information. He is examining medieval geometry manuscripts, where it's usually possible to identify scribes errors.

"I want to get at how secure a mechanism of information transmission it is to have scribes copying manuscripts," he says. "How much gets lost in transcription? I think that's a very promising area to explore."
By Erica Klarreich
COPYRIGHT 2005 Science Service, Inc.

Tuesday, September 4, 2007

BIOLOGY AND BILL GATES

William H. Gates III had his pick of dinner companions at the World Economic Forum in Davos, Switzerland, last January. But one night, instead of dining with foreign dignitaries or business leaders, the Microsoft Corp. chairman met with a handful of distinguished scientists. At the table were Bruce Alberts, president of the National Academy of Sciences; Ilan Chet, president of Israel's Weizmann Institute of Science; and Sir Robert May, president of the Royal Society of London, among others. For more than three hours, the group brainstormed about how to fix some of the world's most vexing public-health dilemmas.
Gates calls biology a hobby. But biologists who have spent time with him say he's no lightweight when it comes to science -- and he's also a major player on the business side. Through the Bill & Melinda Gates Foundation, he has committed more than $3 billion in the past five years to bringing basic health care to developing nations. Gates estimates that his personal investments in biotech companies are worth $300 million to $400 million. And on Apr. 24, he was poised to announce another major contribution -- a $70 million grant to help the University of Washington build a new home for its departments of genome sciences and bioengineering.
Gates says the grant doesn't augur a new focus on gene sciences at his foundation. His chief preoccupation continues to be tackling infectious diseases and other scourges in Africa, Asia, and Latin America. ``The real missing element is applying biology to the diseases of the developing world,'' he explains. ``That's where the market mechanism doesn't work.'' The government and big pharmaceutical companies will go on investing heavily in genomics. But only philanthropy can create financial incentives to treat such common Third World afflictions as tuberculosis and meningitis. And in such areas, says Alberts, ``he's making a huge difference.''
Gates's early forays into biotech were fueled more by fascination with biology than beneficence. In 1990, he invested in Icos Corp., a Bothell (Wash.) company that developed an erectile dysfunction drug. This remains his largest biotech holding, and he still sits on the board. Through the 1990s he added other stakes. But recently, he has eased up on such investments, instead channeling his biomedical efforts through the foundation. Gates sat down with BusinessWeek Seattle Bureau Chief Jay Greene to talk about his gift to the University of Washington and his fascination with the field. Edited excerpts of their conversation follow:
What do you hope will be the impact of the grant?
The University of Washington is one of a reasonably small number of places that has a critical mass of people with genomic expertise. There are some very exciting frontiers in this work that have yet to be tackled, even though the basic sequencing project [the Human Genome Project] is now essentially done. With this grant, coupled with the kind of operating money they'll get, mostly from the government, they'll be able to do a huge amount of work.
Do you see an opportunity to fund more genomics research?
Our foundation, in general, does not fund basic biology research activities. And this grant does not represent a new direction for our global health program. If my dad [who sits on the university's board of regents] wasn't involved in this campaign, if the university weren't part of this community, this wouldn't have made our list of things to give to.
Won't genomics facilitate vaccine research for diseases that afflict the developing world?
Absolutely. Solutions to all biological problems are greatly advanced by the sequencing work and the new tools that are created. The pace of progress in biology creates a foundation that naturally gets picked up by the biotech and pharmaceutical industry to solve rich-world diseases. This is attractive science. It's science that people want to work on. At the same time, the leverage that we do in our developing-world work is greatly advanced by the basic funding from the National Institutes of Health.
In an essay seven years ago, you wrote that biotech was a hobby. What is it that intrigues you so much?
My fascination is broadly with biology and the fact that our increased understanding of biology allows for breakthroughs in a broad set of diseases. Most of my biology reading nowadays is like something I read this weekend, an article on tuberculosis. The week before that, it was a book called AIDS in the Twenty-First Century [by Tony Barnett]. I like to read general biology -- things about the immune system and advances in that area -- because it lays the foundation for my part of the dialogue at the foundation about what things we ought to pursue. The human body is the most complex system ever created. The more we learn about it, the more appreciation we have about what a rich system it is. We really are scratching the surface.
I'm curious about your self-education in this area. There's a story about your going on vacation to Hawaii and polishing off James D. Watson's Molecular Biology of the Gene.
That was Brazil. [Gates pulls a copy from his bookshelf.] It's fun to read about this stuff. When I was in school, I took a lot more physics, chemistry, and math than I did biology. And those are all fields that I still like to read about. But the amount of reading I end up doing that's related to evolution and biology is huge. Almost everyone I talk to reads [Richard] Dawkins, [Steven] Pinker, [Stephen Jay] Gould, which is all evolutionary stuff. There's a level of this reading that I do simply because I'm interested. But I don't think I would have spent time learning about the immune system if understanding vaccines weren't something I considered very important.
Do you still handle most of your biotech investing yourself?
In the last few years, we haven't done much biotech investing. If you go back four or five years, we did some. I had some involvement in each biotech investment, because it was a science-related thing. I have friends who are interested. So they're often bringing me things -- some good, some not so good.
If there were all the time in the world, going out and finding neat new biotech companies might be a fun thing to do. The time I spend reading about biology-related topics has been very focused on developing-world diseases -- so that I can be articulate about those things. Recently, because of the foundation, I haven't focused that much on biotech.
Tell me about your dinner at Davos with Alberts, Chet, California Institute of Technology President David Baltimore, and NIH Director Elias Zerhouni.
It was quite an international group. I was saying: ``Look, what's going on? Why haven't there been faster advances in AIDS treatments? What are the basic scientific questions around this that we don't understand?'' It was a wide-ranging conversation and a great privilege to sit and talk with those guys. They're all people we will be collaborating with.
Copyright © 2000-2007, by The McGraw-Hill Companies Inc. All rights reserved.